Molecular diagnosis on tissues and cells: How it affects training and will affect practice in the future

Cytopathology

Volumn 23, Issue 5, 2012, Pages 286-294

  Boyd, C ^a   Boyle, D P ^b  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Cytopathology; Histopathology; Molecular diagnostic techniques; Pathology training; Personalized medicine

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BIOLOGICAL MARKER; CETUXIMAB; CRIZOTINIB; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; IMMUNOGLOBULIN; K RAS PROTEIN; MAMMAGLOBIN; MISMATCH REPAIR PROTEIN; MISMATCH REPAIR PROTEIN PMS2; PANITUMUMAB; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN TYROSINE KINASE INHIBITOR; RNA; SORAFENIB; T LYMPHOCYTE RECEPTOR; TRASTUZUMAB;

ASPIRATION CYTOLOGY; BREAST CANCER; CHROMOSOME TRANSLOCATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ASSESSMENT; CLINICAL LABORATORY; CLINICAL PRACTICE; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; CYTOLOGY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DRUG TARGETING; ENDOSCOPIC BIOPSY; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENE REARRANGEMENT; HEMATOLOGIC MALIGNANCY; HEMATURIA; HERITABILITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAOPERATIVE PERIOD; LABORATORY DIAGNOSIS; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MEDICAL RESEARCH; MEDICAL SOCIETY; MELANOMA; META ANALYSIS (TOPIC); MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MOLECULAR BIOLOGY; NUCLEIC ACID AMPLIFICATION; ONE STEP NUCLEIC ACID AMPLIFICATION; PATHOLOGIST; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; RECEPTOR GENE; REVIEW; RISK; SARCOMA; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE; STAFF TRAINING; STOMACH CANCER; THYROID CARCINOMA; THYROID NODULE; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR CLASSIFICATION; TUMOR DIAGNOSIS; UNITED KINGDOM; URINE CYTOLOGY; UTERINE CERVIX CYTOLOGY; WART VIRUS;

HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LONDON; NEOPLASMS; PATHOLOGY, MOLECULAR; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 84866520896     PISSN: 09565507     EISSN: 13652303     Source Type: Journal    
DOI: 10.1111/j.1365-2303.2012.01004.x     Document Type: Review

References (66)

1. Royal College of Pathology. Molecular diagnosis on tissues and cells. Bull Royal Coll Pathol 2011;156:306.
2. Burton JL, Wells M. The Alder Hey affair: implications for pathology practice. J Clin Pathol 2001;54:820-3.
3. Jacobson J. Director's challenge: toward a molecular classification of tumors. 1999; Available at: http://grants.nih.gov/grants/guide/rfa-files/rfa-ca-98-027.html [Accessed 15 December 2011].
4. Heffner D. The end of surgical pathology. Ann Diagn Pathol 2001;5:368-73.
5. Rosai J. The continuing role of morphology in the molecular age. Mod Pathol 2001;14:258-60.
6. Williams ED, Sobrinho-Simoes M. Surgical pathology versus molecular biology. Int J Surg Pathol 2001;9:1-3.
7. Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem 1962;237:1555-62.
8. Curriculum for specialty training in histopathology: joint committee on pathology training. Unique document number G051. 2010; Available at: http://www.rcpath.org/NR/rdonlyres/C95ED057-1C10-45F7-94FC-C16E2DADCBB2/0/histopathology_curriculum_ar.pdf [Accessed 26 May 2012].
9. Schmitt F, Barroca H. Role of ancillary studies in fine-needle aspiration from selected tumors. Cancer Cytopathol 2012;120:145-60.
10. Eloy C, Amendoeira I, Schmitt FC. Fine-needle aspiration as an alternative method for frozen tissue banking of breast cancer. Diagn Cytopathol 2009;37:76-7.
11. Visscher DW, Wallis T, Ritchie CA. Detection of chromosome aneuploidy in breast lesions with fluorescence in situ hybridization: comparison of whole nuclei to thin tissue sections and correlation with flow cytometric DNA analysis. Cytometry 1995;21:95-100.
12. Moore JG, To V, Patel SJ, Sneige N. HER-2/neu gene amplification in breast imprint cytology analyzed by fluorescence in situ hybridization: direct comparison with companion tissue sections. Diagn Cytopathol 2000;23:299-302.
13. Salto-Tellez M, Koay ES. Molecular diagnostic cytopathology: definitions, scope and clinical utility. Cytopathology 2004;15:252-5.
14. Clark J, Rocques PJ, Crew AJ et al. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet 1994;7:502-8.
15. Ladanyi M, Gerald W. Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. Cancer Res 1994;54:2837-40.
16. Bovee JV, Hogendoorn PC. Molecular pathology of sarcomas: concepts and clinical implications. Virchows Arch 2010;456:193-9.
17. Dalla-Favera R, Bregni M, Erikson J et al. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 1982;79:7824-7.
18. Yunis JJ, Oken MM, Kaplan ME et al. Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. N Engl J Med 1982;307:1231-6.
19. Le Beau MM, Bitter MA, Larson RA et al. The t(2;5)(p23;q35): a recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma. Leukemia 1989;3:866-70.
20. Fusco A, Chiappetta G, Hui P et al. Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. Am J Pathol 2002;160:2157-67.
21. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
22. Travis WD, Brambilla E, Noguchi M et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-85.
23. Santis G, Angell R, Nickless G et al. Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR. PLoS ONE 2011;6:e25191.
24. Ko HM, da Cunha Santos G, Darling G et al. Diagnosis and subclassification of lymphomas and non-neoplastic lesions involving mediastinal lymph nodes using endobronchial ultrasound-guided transbronchial needle aspiration. Diagn Cytopathol 2011. [Epub ahead of print].
25. Griffin AC, Schwartz LE, Baloch ZW. Utility of on-site evaluation of endobronchial ultrasound-guided transbronchial needle aspiration specimens. Cytojournal 2011;8:20.
26. Micames CG, McCrory DC, Pavey DA, Jowell PS, Gress FG. Endoscopic ultrasound-guided fine-needle aspiration for non-small cell lung cancer staging: a systematic review and metaanalysis. Chest 2007;131:539-48.
27. Monaco SE, Schuchert MJ, Khalbuss WE. Diagnostic difficulties and pitfalls in rapid on-site evaluation of endobronchial ultrasound guided fine needle aspiration. Cytojournal 2010;7:9.
28. Smouse JH, Cibas ES, Janne PA et al. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer 2009;117:67-72.
29. Aisner DL, Deshpande C, Baloch Z et al. Evaluation of EGFR mutation status in cytology specimens: an institutional experience. Diagn Cytopathol 2011. [Epub ahead of print].
30. Pang NK, Nga ME, Chin SY et al. KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma. Cytopathology 2011;22:358-64.
31. Italiano A, Saint-Paul MC, Caroli-Bosc FX et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications. Ann Oncol 2005;16:1503-7.
32. Han HS, Eom DW, Kim JH et al. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases. Clin Lung Cancer 2011;12:380-6.
33. Chang YL, Wu CT, Shih JY, Lee YC. Comparison of p53 and epidermal growth factor receptor gene status between primary tumors and lymph node metastases in non-small cell lung cancers. Ann Surg Oncol 2011;18:543-50.
34. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007;28:742-62.
35. Nikiforov YE. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med 2011;135:569-77.
36. Caronia LM, Phay JE, Shah MH. Role of BRAF in thyroid oncogenesis. Clin Cancer Res 2011;17:7511-7.
37. FDA. Summary of safety and effectiveness data. 2005; Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf3/P030052b.pdf [Accessed 16 December 2011].
38. Bubendorf L. Multiprobe fluorescence in situ hybridization (UroVysion) for the detection of urothelial carcinoma - FISHing for the right catch. Acta Cytol 2011;55:113-9.
39. Bubendorf L, Grilli B, Sauter G et al. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 2001;116:79-86.
40. Hajdinjak T. UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol 2008;26:646-51.
41. May M, Hakenberg OW, Gunia S et al. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice. Urology 2007;70:449-53.
42. Yoder BJ, Skacel M, Hedgepeth R et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 2007;127:295-301.
43. Stintzing S, Heinemann V, Moosmann N et al. The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status. Dtsch Arztebl Int 2009;106:202-6.
44. Eccles SA. The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia 2001;6:393-406.
45. McKeage K, Perry CM. Trastuzumab. A review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 2002;62:209-43.
46. Hofmann M, Stoss O, Shi D et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797-805.
47. Abel K, Black D, Bryden D et al. National Institute for Health and Clinical Excellence: final appraisal determination: trastuzumab for the treatment of HER2-positive metastatic gastric cancer. 2010; Available at: http://www.nice.org.uk/nicemedia/live/12152/50911/50911.pdf [Accessed 15 February 2012].
48. Lee S, de Boer WB, Fermoyle S, Platten M, Kumarasinghe MP. Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology 2011;59:832-40.
49. Layfield DM, Agrawal A, Roche H, Cutress RI. Intraoperative assessment of sentinel lymph nodes in breast cancer. Br J Surg 2011;98:4-17.
50. Castellano I, Macri L, Deambrogio C et al. Reliability of whole sentinel lymph node analysis by one-step nucleic acid amplification for intraoperative diagnosis of breast cancer metastases. Ann Surg 2012;255:334-42.
51. Sagara Y, Ohi Y, Matsukata A et al. Clinical application of the one-step nucleic acid amplification method to detect sentinel lymph node metastasis in breast cancer. Breast Cancer 2011. [Epub ahead of print].
52. Vilardell F, Novell A, Martin J et al. Importance of assessing CK19 immunostaining in core biopsies in patients subjected to sentinel node study by OSNA. Virchows Arch 2012;460:569-75.
53. Cutress RI, McDowell A, Gabriel FG et al. Observational and cost analysis of the implementation of breast cancer sentinel node intraoperative molecular diagnosis. J Clin Pathol 2010;63:522-9.
54. Backus J, Laughlin T, Wang Y et al. Identification and characterization of optimal gene expression markers for detection of breast cancer metastasis. J Mol Diagn 2005;7:327-36.
55. Jass JR. HNPCC and sporadic MSI-H colorectal cancer: a review of the morphological similarities and differences. Fam Cancer 2004;3:93-100.
56. Boland CR, Thibodeau SN, Hamilton SR et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-57.
57. de Jong AE, van Puijenbroek M, Hendriks Y et al. Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer. Clin Cancer Res 2004;10:972-80.
58. Lasota J, Miettinen M. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Semin Diagn Pathol 2006;23:91-102.
59. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
60. Menzies A, Visintin L, Chatfield M. BRAF mutation by age-decade and body mass index in metastatic melanoma. 2011; Available at: http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=78659 [Accessed 10 January 2012].
61. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
62. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
63. Morilla A, Gonzalez de Castro D, Del Guidice I et al. Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL. Leuk Lymphoma 2008;49:2108-15.
64. Zenz T, Eichhorst B, Busch R et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010;28:4473-9.
65. Peach J, Hemsley F, Jones L. Cancer Research UK stratified medicine programme. 2011; Available at: http://science.cancerresearchuk.org/research/how-we-deliver-our-research/others/by-programme/stratified-medicine-programme/ [Accessed 19 December 2011].
66. Lauwers GY, Black-Schaffer S, Salto-Tellez M. Molecular pathology in contemporary diagnostic pathology laboratory: an opinion for the active role of surgical pathologists. Am J Surg Pathol 2010;34:115-7.